Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 25 symbols : SNY save search
Insights on the Antacids Global Market to 2026 - Increasing Awareness About GERD Presents Opportunities
Published: 2021-06-25 (Crawled : 17:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.06%
H: 0.53%
C: 0.3%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.26%
H: 1.13%
C: 0.78%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
Pfizer Pauses Global Sales of Smoking-Cessation Drug Chantix Over Possible Carcinogen Contamination
Published: 2021-06-25 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
sales drug
Pfizer Pauses Global Sales of Smoking-Cessation Drug Chantix Over Possible Ca...
Published: 2021-06-25 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
sales drug
Global $95.9 Billion Vaccines Markets, 2015-2019, 2023F, 2025F, 2030F
Published: 2021-06-25 (Crawled : 14:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.09%
C: -0.13%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.26%
H: 1.13%
C: 0.78%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
vaccine market
BioSpace Movers & Shakers, June 25
Published: 2021-06-25 (Crawled : 14:00) - biospace.com/
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.07%
H: 0.55%
C: -0.43%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.13%
H: 0.32%
C: -0.26%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.26%
H: 1.13%
C: 0.78%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
AGTC | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: -1.97%
H: 0.24%
C: -2.72%
space spac
Global Gene Therapy Markets Report 2021-2030: Antigen, Cytokine, Suicide Gene, Viral Vector, Non-Viral Vector, Oncological, Rare Diseases, Cardiovascular, Neurological Disorders, Infectious Diseases
Published: 2021-06-25 (Crawled : 11:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.09%
C: -0.13%
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: 0.73%
H: 2.08%
C: 2.01%
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.15%
H: 1.37%
C: 0.75%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: -0.45%
H: 1.88%
C: 1.3%
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: -4.89%
AGTC | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: -1.97%
H: 0.24%
C: -2.72%
disease neurological cardiovascular infectious disease gene therapy therapy cardio gene therapies rare
Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression
Published: 2021-06-25 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
treatment lung cancer europe cancer
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Published: 2021-06-25 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
immunotherapy europe therapy cell carcinoma
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
treatment lung cancer europe cancer
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
immunotherapy europe therapy cell carcinoma
Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.